Mankind Pharma Stock Performance Analyzed
Mankind Pharma’s stock price jumped 1.94% today, reaching Rs 2228.7 on the NSE. This positive movement is part of a five-day winning streak. However, despite this recent increase, the company’s stock has still seen a significant drop over the past year.
Key Points
- Stock rose 1.94% today, a positive daily trend.
- Overall, Mankind Pharma is down 23.43% in the last year.
- NIFTY and Nifty Pharma outperformed Mankind Pharma significantly.
- Stock gained 0.27% in the last month, a small recovery.
- Trading volume was 3.36 lakh shares, slightly lower than usual.
- PE ratio stands at 54.2, suggesting the stock is relatively expensive.
Comparing Mankind Pharma to the overall market, it’s important to note that the NIFTY index rose by 10.32% over the same period. The Nifty Pharma index also climbed by 1.52%. This shows that Mankind Pharma hasn’t kept pace with the broader market or its own industry.
The stock’s recent gain of 0.27% over the last month is a small improvement, but it’s still much lower than the performance of the Nifty Pharma index, which increased by 1.82% during the same time. The Nifty Pharma index closed at 22927.9 today, down 0.11%.
Trading activity today involved 3.36 million shares, which is a bit less than the average of 4.94 million shares traded over the past month. The December futures contract for Mankind Pharma increased by 2.1% to Rs 2231.3.
Understanding the company’s price-to-earnings (PE) ratio is also important. A PE of 54.2 means investors are paying a lot for each dollar of the company’s earnings. This can sometimes indicate that the stock is overvalued.
The long-term success of Mankind Pharma depends on its ability to consistently grow its earnings and justify its higher valuation.
